Rethinking Seborrheic Dermatitis in 2026: PDE4 Inhibitors, Luliconazole, and Microbiome-Driven Care
At the 2026 Masterclasses in Dermatology Annual Meeting, Brad P. Glick, DO, MPH, delivered a comprehensive and clinically grounded update on seborrheic dermatitis (SD), emphasizing that although SD is common and chronic, its management is evolving rapidly.
He defined SD as a “chronic and relapsing papulosquamous disorder with yellowish, waxy, brawny scaling” distributed along sebaceous-rich areas, including the scalp, face, nasolabial folds, and chest. The condition affects 1% to 3% of immunocompetent adults and follows a trimodal age distribution: infancy, puberty, and mid-to-late adulthood.
Pathogenesis remains multifactorial. Malassezia species are considered triggering rather than strictly causative, interacting with immune pathways and barrier dysfunction. Current understanding highlights 3 major pillars: alteration of the skin microbiome, sebaceous gland dysfunction, and host immune response, with genetic predisposition as a possible contributor.
First-line therapy continues to center on topical antifungals (ketoconazole, ciclopirox, and terbinafine) and short courses of low- to mid-potency corticosteroids. Calcineurin inhibitors and keratolytics offer steroid-sparing and adjunctive strategies.
Among emerging antifungal options, luliconazole shampoo demonstrated a 68% reduction in Seborrheic Dermatitis Severity Score at 4 weeks compared with 57.9% for ketoconazole. More patients achieved excellent-to-moderate Physician Global Assessment responses, with improved tolerability and cosmetic acceptability.
The most significant pharmacologic advance is topical PDE4 inhibition. Roflumilast 0.3% foam, the first PDE4 inhibitor approved for SD, achieved significantly higher Investigator Global Assessment success at week 8 vs the vehicle (79.5% vs 58.0%; P < .0001). Adverse event rates were low and comparable to the vehicle.
Dr Glick also reviewed investigational and off-label options. Tapinarof, a topical aryl hydrocarbon receptor agonist, may modulate Th17 and Th2 pathways while supporting barrier restoration. Topical JAK inhibitors such as ruxolitinib 1.5% cream have shown favorable outcomes in refractory facial SD, particularly in steroid-averse patients. Oral JAK inhibitors may benefit overlapping atopic dermatitis/SD phenotypes, although paradoxical seborrheic-like eruptions have been reported.
Biologics targeting IL-17, IL-23, and IL-4/IL-13 pathways remain off label for SD but may play a role in recalcitrant cases with comorbid psoriasis or atopic dermatitis. Microbiome-directed therapies, including probiotics, postbiotics, and prebiotics, represent a growing research frontier, although clinical data specific to SD remain limited.
Dr Glick concluded by reminding clinicians that SD may be associated with systemic conditions, such as HIV and Parkinson’s disease, and “may be one of the earliest presenting signs.”
With pathway-targeted therapies and improved antifungals now available, SD management in 2026 is increasingly mechanism-driven, personalized, and proactive.
For more meeting coverage, visit the Masterclasses in Dermatology newsroom.
Reference
Glick BP. Seborrheic dermatitis: management in 2026. Presented at: Masterclasses in Dermatology; February 19–22, 2026; Sarasota, FL.
